Roivant Sciences ($ROIV) Insider Trading & Smart Money Activity
Roivant Sciences Ltd. ($ROIV) has 16 insider trades, 6 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 6 insiders sold ($132.96M), net -$132.96M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 6
- Net insider $ (12 mo)
- -$132.96M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 6
- Analyst ratings on file
- 2
ROIV insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 8 · $124.99M | 0 / 0 | 2 / 2 |
| Q3 2026 | 0 | 1 · $7.32M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $640.86K | 0 / 0 | 1 / 1 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ROIV insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13F | Cache Advisors | Reduced | -179.82K sh | $13.12M | — | ||||||
| 13F | IFM Investors | New | +128.83K sh | $4.71M | Read | ||||||
| Analyst | Wolfe Research | Lowers to Peer Perform | Read | ||||||||
| Insider | Epperly Melissa B,Director | Sell (Open-market sale) 10b5-1 | 17.75K sh | $640.86K | -3.6% | — | |||||
| Insider | Venker EricPresident & Immunovant CEO | Sell (Open-market sale) 10b5-1 | 200K sh | $7.32M | -5.0% | — | |||||
| Analyst | Stifel | Reiterates to Buy | PT $51 | -9.6% | — | ||||||
| Insider | Qvt Financial LP | Sell (Open-market sale) | 12.38K sh | $436.77K | +2.6% | -2.5% | Read | ||||
| Insider | Keith Manchester | Sell (Open-market sale) | 200K sh | $7.09M | +2.6% | -2.5% | Read | ||||
| Insider | Gold Daniel Allen | Sell (Open-market sale) | 12.38K sh | $436.77K | +2.6% | -2.5% | Read | ||||
| Insider | Qvt Financial LP | Sell (Open-market sale) | 800K sh | $27.64M | +1.9% | -5.4% | Read | ||||
| Insider | Keith Manchester | Sell (Open-market sale) | 800K sh | $27.64M | +1.9% | -5.4% | Read | ||||
| Insider | Gold Daniel Allen | Sell (Open-market sale) | 800K sh | $27.64M | +1.9% | -5.4% | — | ||||
| Insider | Mayukh SukhatmePresident & CIO | Sell (Open-market sale) | 500K sh | $17.04M | +3.9% | +1.9% | — | ||||
| Insider | Mayukh SukhatmePresident & CIO | Buy (Option exercise) | 500K sh | $1.93M | +3.9% | +1.9% | — | ||||
| Insider | Mayukh SukhatmePresident & CIO | Sell (Open-market sale) | 500K sh | $17.07M | +3.3% | +2.1% | Read | ||||
| Insider | Mayukh SukhatmePresident & CIO | Buy (Option exercise) | 500K sh | $1.93M | +3.3% | +2.1% | Read | ||||
| Insider | Eric VenkerPresident & Immunovant CEO | Sell (Option exercise) | 200K sh | +3.0% | +2.9% | Read | |||||
| Insider | Eric VenkerPresident & Immunovant CEO | Buy (Option exercise) | 200K sh | $770K | +3.0% | +2.9% | Read | ||||
| Insider | Richard PulikCFO | Sell (Tax withholding) | 2.13K sh | $66.91K | +11.1% | +9.0% | Read | ||||
| Insider | Jennifer HumesChief Accounting Officer | Sell (Tax withholding) | 3.58K sh | $112.58K | +11.1% | +9.0% | Read | ||||
| 13F | Farallon Capital Management | Added | +9.64M sh | $336.01M | +2.3% | +2.5% | Read | ||||
| 13F | Farallon Capital Management | Added | +9.64M sh | $290.64M | +2.3% | +2.5% | — | ||||
| 13F | Baker Bros. Advisors | Reduced | -687.29K sh | $169.06M | +2.3% | +2.5% | Read | ||||
| 13F | Baker Bros. Advisors | Reduced | -687.29K sh | $146.23M | +2.3% | +2.5% | — |
1W / 1M / 6M = how ROIV moved from the trade or filing date.
Insider trading in ROIV: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Epperly Melissa B, | Director | 1 | -$640.86K | Oct 1, 2026 | |
| Venker Eric | President & Immunovant CEO | 1 | -$7.32M | Sep 30, 2026 | |
| Qvt Financial LP | 2 | -$28.08M | Jun 30, 2026 | ||
| Keith Manchester | 2 | -$34.73M | Jun 30, 2026 | ||
| Gold Daniel Allen | 2 | -$28.08M | Jun 30, 2026 | ||
| Mayukh Sukhatme | President & CIO | 4 | -$34.10M | Jun 26, 2026 | |
| Eric Venker | President & Immunovant CEO | 2 | — | Jun 24, 2026 | |
| Richard Pulik | CFO | 1 | — | Jun 20, 2026 | |
| Jennifer Humes | Chief Accounting Officer | 1 | — | Jun 20, 2026 |
Institutions moving ROIV (13F)
Analyst ratings on ROIV
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Wolfe Research | Lowers | Peer Perform | Read | |||||
| Stifel | Reiterates | Buy | $51 | -9.6% | — |
Frequently asked questions
Are ROIV insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 6 insiders made 10 open-market sales worth $132.96M, a net -$132.96M.
What is the latest insider trade in ROIV?
Epperly Melissa B,, Director filed a sell (open-market sale) of 17.75K sh worth $640.86K on Oct 1, 2026.
Which institutions changed their ROIV positions?
Recent 13F filers moving the stock include Farallon Capital Management, Baker Bros. Advisors, Cache Advisors and IFM Investors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.